Prognostic and Predictive Biomarkers of Prostate Cancer
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (1 July 2022) | Viewed by 15403
Special Issue Editors
Interests: Oncogenetics; cancer biomarkers; tumor markers; companion diagnostic tests; prostate and breast cancers
Interests: prostate cancer; bladder cancer; breast cancer; oncology-radiotherapy
Interests: Bladder cancer; prostate cancer
Special Issue Information
Dear Colleagues,
Prostate cancer is the most common cancer in men. The median age of diagnosis is just before the age of 70, and the five-year survival rate is 94%. Prostate cancer generally presents a good prognosis, and it can, thus, be discussed with the patient of whether to avoid a diagnostic biopsy in certain clinical situations of suspected prostate cancer. In the case of a positive biopsy, there are different options to consider, such as active surveillance, watchful waiting, or the initiation of local treatment. To guide the patient’s choice between these options, it is necessary to determine the prognosis of the disease and define the stage of the cancer. Prostate cancer staging is based on the tumor extent using TNM categories, the PSA level and the Gleason score (Grade group). Risk groups, based on PSA, digital rectal examination, and biopsy, from very low to very high are used to determine treatment options, but they are not perfect indicators of the risk. There are ongoing efforts to develop new biomarkers, based on blood or tissue testing, that can aid clinicians in determining which cancers are supposed to be aggressive and need specific treatment.
Biomarkers could also be used to improve the early detection of prostate cancer, to avoid negative biopsies and other diagnoses, to avoid repeated biopsies, and to reduce the number of different diagnostic procedures (MRI, biopsy, other biomarkers, etc.). Recently, targeted therapies have been developed to treat metastatic prostate cancers, and biomarkers predictive of response or resistance to these treatments could be used for the management of these patients. There is currently a need to technically and clinically validate these biomarkers. This Special Issue will focus on the evaluation of the use of new biomarkers in different clinical settings to improve prostate cancer management.
Dr. Pierre Jean Lamy
Prof. Christophe Hennequin
Dr. Mathieu Roumiguie
Dr. Xavier Rebillard
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- biomarkers
- diagnostic test
- screening
- prognosis
- active surveillance
- watchful waiting
- risk groups
- targeted therapy
- companion diagnostic test
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.